A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
Primary Purpose
Osteoarthritis, Pain
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Venlafaxine
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring osteoarthritis pain, activity limitation, antidepressant, depression, single-blind
Eligibility Criteria
Inclusion Criteria:
- Age 50 - 80 years
- Physician diagnosis of OA in hip, knee or spine
- Significant activity limitation due to pain for at least one month on the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) and average pain more than 5/10 on Brief Pain Inventory despite adequate treatment with acetaminophen or NSAIDs (This will identify an OA group with significant psychological distress and a desire for treatment).
- Depression status is not restricted, but will be monitored with PRIME-MD interview and the SCL-20. We anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation.
Exclusion Criteria:
- Cannot read and write English
- Significant cognitive impairment
- History of psychosis or mania
- Current suicidal ideation
- Current substance abuse or dependence
- Current use of opioids or any antidepressant medication
- Use of investigational drug within the past month
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
A
Arm Description
All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
Outcomes
Primary Outcome Measures
Difference in average pain intensity on Brief Pain Inventory
Difference in pain intensity on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
Secondary Outcome Measures
Difference in pain interference on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
Difference in role function as assessed by the Sheehan Disability Scale
Difference in observed physical function as assessed by the Aggravated Locomotor Function Score
Full Information
NCT ID
NCT00611676
First Posted
January 25, 2008
Last Updated
January 25, 2008
Sponsor
University of Washington
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT00611676
Brief Title
A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
Official Title
A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
Study Type
Interventional
2. Study Status
Record Verification Date
January 2008
Overall Recruitment Status
Completed
Study Start Date
September 2004 (undefined)
Primary Completion Date
February 2007 (Actual)
Study Completion Date
February 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Washington
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This will be a single-blind, placebo-run-in trial. Subjects will be informed that they may receive Venlafaxine or placebo during the course of the trial. All subjects will, in fact, receive placebo for the first two weeks. All subjects will then be placed on 150-225 mg per day of venlafaxine. Primary outcome assessment will compare pain intensity at 2 weeks (after placebo) to that at 12 weeks (after 10 weeks of Venlafaxine treatment).
Study Hypothesis:
In subjects who continue to have activity-limiting osteoarthritis pain after treatment with acetaminophen or non-steroidal anti-inflammatory agents, 150-225 mg Venlafaxine per day over 10 weeks will provide significant additional pain relief over that achieved with placebo (more than 30% reduction after Venlafaxine treatment).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Pain
Keywords
osteoarthritis pain, activity limitation, antidepressant, depression, single-blind
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Description
All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
Intervention Type
Drug
Intervention Name(s)
Venlafaxine
Intervention Description
Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
Primary Outcome Measure Information:
Title
Difference in average pain intensity on Brief Pain Inventory
Time Frame
Between 2 weeks and 12 weeks
Title
Difference in pain intensity on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
Time Frame
Between 2 weeks and 12 weeks
Secondary Outcome Measure Information:
Title
Difference in pain interference on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
Time Frame
Between 2 and 12 weeks
Title
Difference in role function as assessed by the Sheehan Disability Scale
Time Frame
Between 2 and 12 weeks
Title
Difference in observed physical function as assessed by the Aggravated Locomotor Function Score
Time Frame
Between 2 and 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 50 - 80 years
Physician diagnosis of OA in hip, knee or spine
Significant activity limitation due to pain for at least one month on the Western Ontario and McMasters University Osteoarthritis Index (WOMAC) and average pain more than 5/10 on Brief Pain Inventory despite adequate treatment with acetaminophen or NSAIDs (This will identify an OA group with significant psychological distress and a desire for treatment).
Depression status is not restricted, but will be monitored with PRIME-MD interview and the SCL-20. We anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation.
Exclusion Criteria:
Cannot read and write English
Significant cognitive impairment
History of psychosis or mania
Current suicidal ideation
Current substance abuse or dependence
Current use of opioids or any antidepressant medication
Use of investigational drug within the past month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark D. Sullivan, MD, PhD
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain
We'll reach out to this number within 24 hrs